L
Lu-Yao Li
Researcher at Wuhan University
Publications - 6
Citations - 169
Lu-Yao Li is an academic researcher from Wuhan University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 3 publications receiving 58 citations. Previous affiliations of Lu-Yao Li include Henan University.
Papers
More filters
Journal ArticleDOI
Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)
Ying-Hui Jin,Qing-Yuan Zhan,Zhi-Yong Peng,Xue-Qun Ren,Xun-Tao Yin,Lin Cai,Yu-Feng Yuan,Ji-Rong Yue,Xiaochun Zhang,Qi-Wen Yang,Jianguang Ji,Jian Xia,Yi-Rong Li,Fu-Xiang Zhou,Ya-Dong Gao,Zhui Yu,Feng Xu,Ming-Li Tu,Li-Ming Tan,Min Yang,Fang Chen,Xiao-Ju Zhang,Mei Zeng,Yu Zhu,Xin-Can Liu,Jian Yang,Dong-Chi Zhao,Yu-Feng Ding,Ning Hou,Fu-Bing Wang,Hao Chen,Yonggang Zhang,Wei Li,Wen Chen,Yue-Xian Shi,Xiu-Zhi Yang,Xuejun Wang,Yan-Jun Zhong,Ming-Juan Zhao,Bing-Hui Li,Bing-Hui Li,Lin-Lu Ma,Hao Zi,Hao Zi,Na Wang,Yun-Yun Wang,Shao-Fu Yu,Lu-Yao Li,Lu-Yao Li,Qiao Huang,Hong Weng,Xiang-Ying Ren,Xiang-Ying Ren,Li-Sha Luo,Man-Ru Fan,Di Huang,Hong-Yang Xue,Lin-Xin Yu,Jin-Ping Gao,Jin-Ping Gao,Tong Deng,Tong Deng,Xian-Tao Zeng,Hong-Jun Li,Zhen-Shun Cheng,Xiaomei Yao,Xinghuan Wang +66 more
TL;DR: A working group of clinical experts and methodologists searched the literature for direct evidence on the management of COVID-19, and assessed its certainty generated recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.
Posted ContentDOI
Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019.
Hao Zi,Shao-Hua He,Xie-Yuan Leng,Xie-Yuan Leng,Xiao-Feng Xu,Qiao Huang,Hong Weng,Cong Zhu,Lu-Yao Li,Lu-Yao Li,Jia-Min Gu,Xu-Hui Li,Dao-Jing Ming,Dao-Jing Ming,Xiao-Dong Li,Shuai Yuan,Xinghuan Wang,Dalin He,Xian-Tao Zeng +18 more
TL;DR: Of all cancers, incidence, mortality, and DALYs were higher in the high-level SDI regions and countries, and the burden of bladder cancer and prostate cancer was mainly distributed among older men, while theurden of kidney cancer increases among younger men.
Posted ContentDOI
Epidemiological Trends of Urinary Tract Infections, Urolithiasis and Benign Prostatic Hyperplasia in 204 Countries and Territories From 1990 to 2019
Cong Zhu,Dan-Qi Wang,Hao Zi,Qiao Huang,Jia-Min Gu,Lu-Yao Li,Xin-Pei Guo,Fei Li,Cheng Fang,Xiao-Dong Li,Xian-Tao Zeng +10 more
TL;DR: Over the past three decades, the disease burden remains increased in UTI, while decreased in urolithiasis and BPH, and the allocation of medical resources should be more based on the epidemiological characteristics and geographical distribution of diseases.
Journal ArticleDOI
Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats
Lu-Yao Li,Jie Han,Lan Wu,Cheng Fang,Weiguang Li,Jia-Min Gu,Tong Deng,Changrong Qin,Jiayan Nie,Xian-Tao Zeng +9 more
TL;DR: Wang et al. as mentioned in this paper used 16S rDNA sequencing and liquid chromatography tandem mass spectrometry (LC-MS/MS) to investigate the regulation of BPH on gut microbiota composition and metabonomics.
Journal ArticleDOI
A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m6A reader YTHDC1
Shuai Yuan,Shao-Hua He,Lu-Yao Li,Shuqiang Xi,Hong Weng,Jin-Hui Zhang,Dan-Qi Wang,Meng-Meng Guo,Haozhe Zhang,Shuang Wang,Dao-Jing Ming,Meng Yang Liu,Hailiang Hu,Xian-Tao Zeng +13 more
TL;DR: In this article , SLC12A5 was shown to promote tumor progression and castration resistance of prostate cancer through the N6-methyladenosine (m 6 A) reader YTHDC1 and the transcription factor HOXB13.